Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 5,399 matching trials from the live ClinicalTrials.gov search.
Filters: Tucson, Arizona Clear all
Terminated Phase 2 Interventional

A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

NCT06315491
View directory record Official record
Conditions
Platinum-resistant Ovarian Cancer, Refractory Ovarian Carcinoma
Interventions
CBX-12
Drug
Lead sponsor
Cybrexa Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Nov 9, 2026, 5:38 PM EST
Completed Phase 3 Interventional Results available

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

NCT01372150
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
desvenlafaxine succinate sustained release, fluoxetine, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
41
States / cities
Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Nov 9, 2026, 5:38 PM EST
Completed Phase 2 Interventional Results available

Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)

NCT03028350
View directory record Official record
Conditions
Asthma, Aspirin-Induced
Interventions
Ifetroban Oral Capsule, Placebo Oral Capsule
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
16
States / cities
Tucson, Arizona • Lancaster, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Nov 9, 2026, 5:38 PM EST
Completed Phase 3 Interventional

A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients

NCT00002378
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Saquinavir, Delavirdine mesylate, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
97
States / cities
Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 9, 2026, 5:38 PM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis

NCT04124926
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Vonoprazan, Lansoprazole
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
109
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 88 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Nov 9, 2026, 5:38 PM EST
Completed Phase 2 Interventional

GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection

NCT01435226
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
GS-5885, GS-9451, tegobuvir, placebo to match tegobuvir, placebo to match RBV, Ribavirin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
37
States / cities
Tucson, Arizona • Anaheim, California • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Nov 9, 2026, 5:38 PM EST
Terminated Not applicable Interventional Results available

Negative Pressure Wound Therapy With Instillation of Saline Solution Versus Collagenase Ointment in Full-thickness Wounds

NCT03722485
View directory record Official record
Conditions
Wounds and Injuries, Wound Healing, Granulation Tissue
Interventions
Negative Pressure Therapy w/ instillation and dwell (NPWTi-d), Collagenase Ointment
Device · Biological
Lead sponsor
KCI USA, Inc
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Tucson, Arizona • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Nov 9, 2026, 5:38 PM EST
Completed Phase 3 Interventional

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

NCT01508026
View directory record Official record
Conditions
Stage 1 Hypertension, Stage 2 Hypertension
Interventions
Nebivolol and Valsartan 1, Nebivolol and Valsartan 2, Nebivolol and Valsartan 3, Nebivolol 1, Nebivolol 2, Valsartan 1, Valsartan 2, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
4,161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
413
States / cities
Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 290 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2014 · Synced Nov 9, 2026, 5:38 PM EST
Completed Phase 2 Interventional Results available

An Open-label Extension Study of PSMA ADC 2301 in mCRPC

NCT02020135
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSMA ADC
Drug
Lead sponsor
Progenics Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
6
States / cities
Tucson, Arizona • New Orleans, Louisiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Nov 9, 2026, 5:38 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults

NCT04614948
View directory record Official record
Conditions
Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19
Interventions
Ad26.COV2.S, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
31,835 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
63
States / cities
Vestavia Hills, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Nov 9, 2026, 5:38 PM EST
Completed Phase 3 Interventional Results available

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

NCT01313676
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone furoate/vilanterol, fluticasone furoate, vilanterol, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
16,568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
506
States / cities
Andalusia, Alabama • Athens, Alabama • Birmingham, Alabama + 369 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Nov 9, 2026, 5:38 PM EST
Completed Not applicable Interventional Results available

Randomized On-X Anticoagulation Trial

NCT00291525
View directory record Official record
Conditions
Heart Valve Disease
Interventions
On-X valve using reduced anticoagulation, On-X Valve with Standard warfarin Therapy
Device
Lead sponsor
On-X Life Technologies, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
977 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2023
U.S. locations
44
States / cities
Tucson, Arizona • Loma Linda, California • Hartford, Connecticut + 34 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Nov 9, 2026, 5:38 PM EST
Completed Phase 2 Interventional Results available

A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)

NCT02034552
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Abiraterone acetate, Prednisone, Enzalutamide
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
19
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Nov 9, 2026, 5:38 PM EST
Terminated Phase 3 Interventional Results available

Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease

NCT00349752
View directory record Official record
Conditions
Crohn's Disease
Interventions
certolizumab pegol 400 mg, Placebo
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
54
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Nov 9, 2026, 5:38 PM EST
Completed Phase 4 Interventional Results available

A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)

NCT02138747
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Mirabegron, Tolterodine ER
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
22
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Nov 9, 2026, 5:38 PM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Feasibility of Virtual Tai Chi Easy for Registered Nurses

NCT06423638
View directory record Official record
Conditions
Transition Shock, Nurses' Intention to Quit, Stress, Somatic Symptoms, Burnout, Trauma and Stressor Related Disorders
Interventions
Virtual Tai Chi Easy
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Nov 9, 2026, 5:38 PM EST
Active, not recruiting Phase 2Phase 3 Interventional

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

NCT05492578
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Topical corticosteroids, Topical calcineurin inhibitors, Oral corticosteroids
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
1,856 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
101
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 9, 2026, 5:38 PM EST
Completed Phase 3 Interventional Results available

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

NCT02631876
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Ovarian Cancer
Interventions
Mirvetuximab soravtansine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan
Drug
Lead sponsor
ImmunoGen, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
53
States / cities
Birmingham, Alabama • Tempe, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Nov 9, 2026, 5:38 PM EST
Completed Phase 4 Interventional

Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease

NCT01983449
View directory record Official record
Conditions
Peripheral Arterial Diseases
Interventions
Dexamethasone Sodium Phosphate Injection, USP
Drug
Lead sponsor
Mercator MedSystems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
38
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Nov 9, 2026, 5:38 PM EST
Terminated Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of CHAM* for the Treatment of Diabetic Foot Ulcers

NCT02571738
View directory record Official record
Conditions
Chronic Diabetic Foot Ulcers
Interventions
CHAM, Control
Biological · Other
Lead sponsor
Osiris Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
18
States / cities
Tucson, Arizona • Carlsbad, California • Castro Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Nov 9, 2026, 5:38 PM EST
Completed Not applicable Interventional

Treating COVID-19 With a Bidirectional Oxygenation Valve

NCT04326452
View directory record Official record
Conditions
Coronavirus Infection
Interventions
bidirectional oxygenation mouthpiece
Device
Lead sponsor
TMC HealthCare
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Tucson, Arizona • Stanford, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Nov 9, 2026, 5:38 PM EST
Active, not recruiting Phase 3 Interventional

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

NCT05899608
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Ivonescimab Injection, Pembrolizumab Injection
Biological
Lead sponsor
Summit Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
76
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 9, 2026, 5:38 PM EST
Completed Phase 3 Interventional Results available

SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

NCT03262935
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
(vic-)trastuzumab duocarmazine, Physician's choice
Drug
Lead sponsor
Byondis B.V.
Industry
Eligibility
18 Years and older · Female only
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
23
States / cities
Mobile, Alabama • Tucson, Arizona • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Nov 9, 2026, 5:38 PM EST
Completed Not applicable Interventional Results available

RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms

NCT05965752
View directory record Official record
Conditions
Long COVID, Long COVID-19, Long COVID19
Interventions
BrainHQ/Active Comparator Activity, BrainHQ, PASC CoRE, tDCS-active, tDCS-sham
Other · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
24
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Nov 9, 2026, 5:38 PM EST